Matches in Wikidata for { <http://www.wikidata.org/entity/Q89621586> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q89621586 description "article scientifique publié en 2019" @default.
- Q89621586 description "artículu científicu espublizáu en payares de 2019" @default.
- Q89621586 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q89621586 description "scientific article published on 01 November 2019" @default.
- Q89621586 description "wetenschappelijk artikel" @default.
- Q89621586 description "наукова стаття, опублікована 1 листопада 2019" @default.
- Q89621586 description "գիտական հոդված հրատարակված 2019 թվականի նոյեմբերի 1-ին" @default.
- Q89621586 name "An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period" @default.
- Q89621586 name "An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period" @default.
- Q89621586 type Item @default.
- Q89621586 label "An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period" @default.
- Q89621586 label "An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period" @default.
- Q89621586 prefLabel "An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period" @default.
- Q89621586 prefLabel "An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period" @default.
- Q89621586 P1433 Q89621586-C5BADAFF-B321-4B3D-B9BF-571D0B946E4D @default.
- Q89621586 P1476 Q89621586-8E2A1F91-0DB4-4151-B5CB-C067CBC0262E @default.
- Q89621586 P2093 Q89621586-51B8FAE2-5166-4F31-BBF6-6793DE01B182 @default.
- Q89621586 P2093 Q89621586-6796DE57-F75E-4AC3-AE7D-7C3AF7041CA3 @default.
- Q89621586 P2093 Q89621586-D4CD9B43-1B03-4791-BFA7-CD9A76EF70DC @default.
- Q89621586 P2860 Q89621586-054F6C99-7B6E-457B-864A-CFCF8632F04A @default.
- Q89621586 P2860 Q89621586-18343203-1EB2-4833-972A-3A987D256DB6 @default.
- Q89621586 P2860 Q89621586-1AF5448D-9C4B-4627-BBD3-09C97946CC25 @default.
- Q89621586 P2860 Q89621586-2F421BA5-6501-4D2F-AE79-6287ABB8A75F @default.
- Q89621586 P2860 Q89621586-4B0BF2A2-D16E-49F1-969F-AAA029F057DB @default.
- Q89621586 P2860 Q89621586-8773AE3D-0BFA-4415-B657-653847447432 @default.
- Q89621586 P2860 Q89621586-8960BA73-4222-428B-B713-0BA7624F86A7 @default.
- Q89621586 P2860 Q89621586-8E4A319B-CE5C-4223-AB1E-37432040B19B @default.
- Q89621586 P2860 Q89621586-B218D824-7C8B-4393-BB27-28295DDAB667 @default.
- Q89621586 P2860 Q89621586-B84C3D12-5409-4F4E-8792-DEE7D026CDE1 @default.
- Q89621586 P2860 Q89621586-EEC82908-A730-42A5-9557-7D5DFEBAD3D8 @default.
- Q89621586 P2860 Q89621586-F24E7F8F-EE5E-462E-B74D-071FCC73ADA7 @default.
- Q89621586 P2860 Q89621586-F29DFBB2-3BE7-45E1-A546-9AF4E6C3FB1E @default.
- Q89621586 P2860 Q89621586-FE3FD99A-B74B-42E4-BD5B-47E779C8F705 @default.
- Q89621586 P304 Q89621586-36166B30-167A-48D8-822D-D5613E78941A @default.
- Q89621586 P31 Q89621586-78B04E1E-EA44-4BD6-82BC-885221B3E957 @default.
- Q89621586 P433 Q89621586-77FE1EAC-19E1-4C83-BE89-0E47AF877B23 @default.
- Q89621586 P478 Q89621586-5355FD38-40E1-47B2-A5D2-1CB7A768EA3A @default.
- Q89621586 P50 Q89621586-DFA21FA0-8669-4C9F-836C-129BC7CFE968 @default.
- Q89621586 P577 Q89621586-469B45D5-38E8-456E-9898-E9CBDC49F1C0 @default.
- Q89621586 P698 Q89621586-BB4E34EA-4A6E-44D0-B5FC-4FA16F377A62 @default.
- Q89621586 P932 Q89621586-D4B30485-080C-41AE-89B1-14C0A1C5E4FD @default.
- Q89621586 P698 32038751 @default.
- Q89621586 P1433 Q26842086 @default.
- Q89621586 P1476 "An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period" @default.
- Q89621586 P2093 "Andrea L Zaenglein" @default.
- Q89621586 P2093 "Jeanett Segal" @default.
- Q89621586 P2093 "Linda Stein Gold" @default.
- Q89621586 P2860 Q24568211 @default.
- Q89621586 P2860 Q33513722 @default.
- Q89621586 P2860 Q34564145 @default.
- Q89621586 P2860 Q34584358 @default.
- Q89621586 P2860 Q34650531 @default.
- Q89621586 P2860 Q34729115 @default.
- Q89621586 P2860 Q34991482 @default.
- Q89621586 P2860 Q36433383 @default.
- Q89621586 P2860 Q38321150 @default.
- Q89621586 P2860 Q42680672 @default.
- Q89621586 P2860 Q44795703 @default.
- Q89621586 P2860 Q48276115 @default.
- Q89621586 P2860 Q51645377 @default.
- Q89621586 P2860 Q68420381 @default.
- Q89621586 P304 "13-18" @default.
- Q89621586 P31 Q13442814 @default.
- Q89621586 P433 "11" @default.
- Q89621586 P478 "12" @default.
- Q89621586 P50 Q98945464 @default.
- Q89621586 P577 "2019-11-01T00:00:00Z" @default.
- Q89621586 P698 "32038751" @default.
- Q89621586 P932 "6937162" @default.